TY - JOUR
T1 - COVID-19 infection among patients with autoinflammatory diseases
T2 - a study on 117 French patients compared with 1545 from the French RMD COVID-19 cohort: COVIMAI-the French cohort study of SARS-CoV-2 infection in patient with systemic autoinflammatory diseases
AU - FAI2R/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors
AU - Bourguiba, Rim
AU - Kyheng, Maeva
AU - Koné-Paut, Isabelle
AU - Rouzaud, Diane
AU - Avouac, Jerome
AU - Devaux, Mathilde
AU - Abdallah, Nassim Ait
AU - Fautrel, Bruno
AU - Ferreira-Maldent, Nicole
AU - Langlois, Vincent
AU - Ledoult, Emmanuel
AU - Nielly, Hubert
AU - Queyrel, Viviane
AU - Sellam, Jérémie
AU - Tieulie, Nathalie
AU - Chazerain, Pascal
AU - Evon, Philippe
AU - Labreuche, Julien
AU - Savey, Léa
AU - Hentgen, Veronique
AU - Grateau, Gilles
AU - Georgin-Lavialle, Sophie
AU - Aeschlimann, Florence
AU - Agard, Christian
AU - Ait-Abdallah, Nassim A.
AU - Albert, Jean David
AU - Alcaix, Didier
AU - Allain, Jean Sébastien
AU - Allanore, Yannick
AU - Amoura, Zahir
AU - Amouzougan, Adamah
AU - Andre, Emma
AU - Arbault, Anaïs
AU - Arlet, Jean Benoît
AU - Arnaud, Laurent
AU - Arniaud, Denis
AU - Arty-Hue, Herliette
AU - Atlan, Lucie
AU - Audemard-Verger, Alexandra
AU - Audoin-Pajot, Christine
AU - Audren, Victor
AU - Avenel, Gilles
AU - Avouac, Jérôme
AU - Bach-Bunner, Maxime
AU - Bacquet-Deschryver, Hélène
AU - Bader-Meunier, Brigitte
AU - Balandraud, Nathalie
AU - Balblanc, Jean Charles
AU - Ballot-Schmit, Claire
AU - Hennequin, Pascal
N1 - Publisher Copyright:
© Author(s) (or their employer(s)) 2022.
PY - 2022/2/1
Y1 - 2022/2/1
N2 - Objective There is little known about SARS-CoV-2 infection in patients with systemic autoinflammatory disease (SAID). This study aimed to describe epidemiological features associated with severe disease form and death. Mortality between patients with and without SAID hospitalised for SARS-CoV-2 infection was compared. Methods A national multicentric prospective cohort study was conducted from the French Rheumatic and Musculoskeletal Diseases (RMD) COVID-19 cohort. Patients with SAID were matched with patients with non-SAID on age±7 years, gender and number of comorbidities to consider important confounding factors. Impact of SAID on severity of SARS-CoV-2 infection was analysed using multinomial logistic regression for severity in three classes (mild, moderate and severe with mild status as reference). Fine-Gray regression model for length of hospital stay and binomial logistic regression model for risk of death at 30 days. Results We identified 117 patients with SAID (sex ratio 0.84, 17 children) and compared them with 1545 patients with non-autoinflammatory immune-mediated inflammatory disorders (non-SAID). 67 patients had a monogenic SAID (64 with familial Mediterranean fever). Other SAIDs were Behçet' disease (n=21), undifferentiated SAID (n=16), adult-onset Still disease (n=9) and systemic-onset juvenile idiopathic arthritis (n=5). Ten adults developed severe form (8.6%). Six patients died. All children had a benign disease. After matching on age±7 years, sex and number of comorbidities, no significant difference between the two groups in length of stay and the severity of infection was noted. Conclusion As identified in the whole French RMD COVID-19 cohort, patients with SAID on corticosteroids and with multiple comorbidities are prone to develop more severe COVID-19 forms.
AB - Objective There is little known about SARS-CoV-2 infection in patients with systemic autoinflammatory disease (SAID). This study aimed to describe epidemiological features associated with severe disease form and death. Mortality between patients with and without SAID hospitalised for SARS-CoV-2 infection was compared. Methods A national multicentric prospective cohort study was conducted from the French Rheumatic and Musculoskeletal Diseases (RMD) COVID-19 cohort. Patients with SAID were matched with patients with non-SAID on age±7 years, gender and number of comorbidities to consider important confounding factors. Impact of SAID on severity of SARS-CoV-2 infection was analysed using multinomial logistic regression for severity in three classes (mild, moderate and severe with mild status as reference). Fine-Gray regression model for length of hospital stay and binomial logistic regression model for risk of death at 30 days. Results We identified 117 patients with SAID (sex ratio 0.84, 17 children) and compared them with 1545 patients with non-autoinflammatory immune-mediated inflammatory disorders (non-SAID). 67 patients had a monogenic SAID (64 with familial Mediterranean fever). Other SAIDs were Behçet' disease (n=21), undifferentiated SAID (n=16), adult-onset Still disease (n=9) and systemic-onset juvenile idiopathic arthritis (n=5). Ten adults developed severe form (8.6%). Six patients died. All children had a benign disease. After matching on age±7 years, sex and number of comorbidities, no significant difference between the two groups in length of stay and the severity of infection was noted. Conclusion As identified in the whole French RMD COVID-19 cohort, patients with SAID on corticosteroids and with multiple comorbidities are prone to develop more severe COVID-19 forms.
U2 - 10.1136/rmdopen-2021-002063
DO - 10.1136/rmdopen-2021-002063
M3 - Article
C2 - 35537796
AN - SCOPUS:85129999718
SN - 2056-5933
VL - 8
JO - RMD Open
JF - RMD Open
IS - 1
M1 - e002063
ER -